Bolt Biotherapeutics reports positive BDC-1001 Phase 1 data; advances to Phase 2; cash $192.8M

Bolt Biotherapeutics, Inc.

BDC-1001 elicited objective responses including partial responses and stable disease across multiple HER2+ solid tumors as monotherapy and with nivolumab.
Phase 2 program to start in 2023: two studies in breast, colorectal, endometrial, and gastroesophageal cancers.
Entered clinical supply agreement with Roche for pertuzumab (Perjeta) to combine with BDC-1001 in breast cancer.
Cash, cash equivalents, and marketable securities of $192.8M as of Dec 31, 2022, expected to fund operations through 2025.
Full-year 2022 collaboration revenue $5.7M; R&D expenses $73.1M; loss from operations $90.3M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Bolt Biotherapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended.

Period: fourth quarter and full year ended December 31, 2022
Revenue: Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended
Result: reported results

Exact text from the filing

– 5:00 p.m. EDT Location: Orange County Convention Center, Section 24 Fourth Quarter and Full Year 2022 Financial Results • Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended December 31, 2022, compared to $0.5 million and $1.3 million for the same quarter and year in 2021. The collaboration

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010609

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.